Great Britain ap­proves sub­cu­ta­neous Tecen­triq weeks ahead of ex­pect­ed US de­ci­sion

Pa­tients in Great Britain who take IV Tecen­triq now have a quick­er op­tion.

The coun­try’s reg­u­la­to­ry au­thor­i­ty has ap­proved a sub­cu­ta­neous ver­sion of ate­zolizum­ab, bet­ter known as Roche’s block­buster im­munother­a­py Tecen­triq. The new ver­sion takes just sev­en min­utes to ad­min­is­ter, as op­posed to 30 to 60 min­utes for the IV for­mu­la­tion, Roche an­nounced on Tues­day.

The news comes weeks ahead of an ex­pect­ed de­ci­sion in the US on Sept. 15, ex­ec­u­tives said on the com­pa­ny’s re­cent Q2 earn­ings call per an Al­phaSense tran­script. In Great Britain, Tecen­triq SC’s la­bel cov­ers all the same in­di­ca­tions as the IV for­mu­la­tion and will be avail­able “in the com­ing weeks,” a spokesper­son told End­points News. The EU’s reg­u­la­to­ry au­thor­i­ty is cur­rent­ly con­sid­er­ing the drug’s use, in­clud­ing in North­ern Ire­land.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER